• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:08:05 PM ET
    $CHMA
    Major Pharmaceuticals
    Health Care
    Get the next $CHMA alert in real time by email
    SC 13G/A 1 d124644dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)*

     

     

    Chiasma, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    16706W 10 2

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 1 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM BioVentures IV-QP, L.P.

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    5,216,482*

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    5,216,482*

       8.   

    Shared Dispositive Power

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,216,482*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    8.8%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    *

    Includes 1,196,908 shares of Common Stock issuable pursuant to warrants, which are exercisable within 60 days of the date of this filing.

     

    Page 2 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM BioVentures IV GmbH & Co. Beteiligungs KG

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Germany

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    200,973*

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    200,973*

       8.   

    Shared Dispositive Power

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    200,973*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.4%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    *

    Includes 46,112 shares of Common Stock issuable pursuant to warrants, which are exercisable within 60 days of the date of this filing.

     

    Page 3 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM Asset Management Investors BV4 LLC

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    148,332*

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    148,332*

       8.   

    Shared Dispositive Power

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    148,332*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    0.3%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    *

    Includes 34,033 shares of Common Stock issuable pursuant to warrants, which are exercisable within 60 days of the date of this filing.

     

    Page 4 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM Bio IV NVS Strategic Fund, L.P.

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Bermuda

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    1,552,960*

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    1,552,960*

       8.   

    Shared Dispositive Power

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,552,960*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    2.7%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    *

    Includes 105,398 shares of Common Stock issuable pursuant to warrants, which are exercisable within 60 days of the date of this filing.

     

    Page 5 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM BioVentures IV GP LLC

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    6,970,415*

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    6,970,415*

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,970,415*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    11.8%

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

     

    *

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by MPM BioVentures IV-QP, L.P. (“BV IV QP”), 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by MPM BioVentures IV GmbH & Co. Beteiligungs KG (“BV KG”) and 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by MPM Bio IV NVS Strategic Fund, L.P. (“BV SF”). The warrants listed above are exercisable within 60 days of the date of this filing. The Reporting Person is the direct general partner of BV IV QP, BV KG and BV SF.

     

    Page 6 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    MPM BioVentures IV LLC

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    7,118,747*

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    7,118,747*

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,118,747*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    12.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    *

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 share of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by MPM Asset Management Investors BV4 LLC (“AM BV4”). The warrants listed above are exercisable within 60 days of the date of this filing. The Reporting Person is the indirect general partner of BV IV QP, BV KG and BV SF and the Manager of AM BV4.

     

    Page 7 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    Luke Evnin

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    7,118,747*

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    7,118,747*

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,118,747*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    12.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    *

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 shares of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by AM BV4. MPM BioVentures IV GP LLC (“MPM IV GP”) and MPM BioVentures IV LLC (“MPM IV LLC”) are the direct and indirect general partners of BV IV QP, BV KG and BV SF. MPM IV LLC is the Manager of AM BV4. The Reporting Person is a member of MPM IV LLC.

     

    Page 8 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    Ansbert Gadicke

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    7,118,747*

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    7,118,747*

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,118,747*

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    12.0%

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    *

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 shares of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by AM BV4. MPM IV GP and MPM IV LLC are the direct and indirect general partners of BV IV QP, BV KG and BV SF. MPM IV LLC is the Manager of AM BV4. The Reporting Person is a member of MPM IV LLC.

     

    Page 9 of 15


    CUSIP No. 16706W 10 2

     

      1.   

    Name of Reporting Persons

     

    Todd Foley

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

      3.  

    SEC USE ONLY

     

        

      4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

    Sole Voting Power

     

    49,000*

       6.   

    Shared Voting Power

     

    7,118,747**

       7.   

    Sole Dispositive Power

     

    49,000*

       8.   

    Shared Dispositive Power

     

    7,118,747**

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,167,747* **

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

        

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    12.1%

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    *

    Includes 49,000 shares of Common Stock issuable pursuant to options which are exercisable within 60 days of December 31, 2020.

    **

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 shares of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by AM BV4. MPM IV GP and MPM IV LLC are the direct and indirect general partners of BV IV QP, BV KG and BV SF. MPM IV LLC is the Manager of AM BV4. The Reporting Person is a member of MPM IV LLC.

     

    Page 10 of 15


    Item 1.

     

      (a)

    Name of Issuer

    Chiasma, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    460 Totten Pond Road, Suite 530

    Waltham MA 02451

     

    Item 2.

     

      (a)

    Name of Person Filing

    MPM BioVentures IV-QP, L.P.

    MPM BioVentures IV GmbH & Co. Beteiligungs KG

    MPM Asset Management Investors BV4 LLC

    MPM Bio IV NVS Strategic Fund, L.P.

    MPM BioVentures IV GP LLC

    MPM BioVentures IV LLC

    Luke Evnin

    Ansbert Gadicke

    Todd Foley

     

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o MPM Capital LLC

    450 Kendall Street

    Cambridge, MA 02142

     

      (c)

    Citizenship

    All entities were organized in Delaware except MPM BioVentures IV GmbH & Co. Beteiligungs KG, which was organized in Germany and MPM Bio IV NVS Strategic Fund, L.P., which was organized in Bermuda. The individuals are all United States citizens.

     

      (d)

    Title of Class of Securities

    Common Stock

     

      (e)

    CUSIP Number

    16706W 10 2

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable

     

    Page 11 of 15


    Item 4.

    Ownership

     

    MPM Entity

       Shares
    Held
    Directly
         Shares
    Issuable
    Upon
    Exercise of
    Warrants
    Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class
     

    BV IV QP

         4,019,574        1,196,908        5,216,482        0        5,216,482        0        5,216,482        8.8 % 

    BV KG

         154,861        46,112        200,973        0        200,973        0        200,973        0.4 % 

    BV SF

         1,447,562        105,398        1,552,960        0        1,552,960        0        1,552,960        2.7 % 

    AM BV4

         114,299        34,033        148,332        0        148,332        0        148,332        0.3 % 

    BV IV GP(1)

         0        0        0        6,970,415        0        6,970,415        6,970,415        11.8 % 

    BV IV LLC(2)

         0        0        0        7,118,747        0        7,118,747        7,118,747        12.0 % 

    Luke Evnin(3)

         0        0        0        7,118,747        0        7,118,747        7,118,747        12.0 % 

    Ansbert Gadicke(3)

         0        0        0        7,118,747        0        7,118,747        7,118,747        12.0 % 

    Todd Foley(3)(4)

         49,000        0        49,000        7,118,747        0        7,118,747        7,167,747        12.1 % 

     

    (1)

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG and 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF. The warrants listed above are exercisable within 60 days of the date of this filing. The Reporting Person is the direct general partner of BV IV QP, BV KG and BV SF.

    (2)

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 shares of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by AM BV4. The warrants listed above are exercisable within 60 days of the date of this filing. The Reporting Person is the indirect general partner of BV IV QP, BV KG and BV SF and the Manager of AM BV4.

    (3)

    Consists of 4,019,574 shares of Common Stock and 1,196,908 shares of Common Stock issuable upon exercise of warrants held by BV IV QP, 154,861 shares of Common Stock and 46,112 shares of Common Stock issuable upon exercise of warrants held by BV KG, 1,447,562 shares of Common Stock and 105,398 shares of Common Stock issuable upon exercise of warrants held by BV SF and 114,299 shares of Common Stock and 34,033 shares of Common Stock issuable upon exercise of warrants held by AM BV4. MPM IV GP and MPM IV LLC are the direct and indirect general partners of BV IV QP, BV KG and BV SF. MPM IV LLC is the Manager of AM BV4. The Reporting Person is a member of MPM IV LLC.

    (4)

    Includes 49,000 shares of Common Stock issuable pursuant to options which are exercisable within 60 days of December 31, 2020.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Page 12 of 15


    Item 9.

    Notice of Dissolution of a Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable

     

    Page 13 of 15


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 11, 2021

     

    MPM BIOVENTURES IV-QP, L.P.     MPM BIOVENTURES IV GMBH & CO. BETEILIGUNGS KG

     

    By:

     

     

    MPM BioVentures IV GP LLC,

         
      its General Partner     By:   MPM BioVentures IV GP LLC,
            in its capacity as the Managing Limited Partner
    By:   MPM BioVentures IV LLC,      
      its Managing Member     By:   MPM BioVentures IV LLC,
            its Managing Member
    By:  

        /s/ Luke Evnin

         
      Name: Luke Evnin     By:  

        /s/ Luke Evnin

      Title:   Member       Name: Luke Evnin
            Title:   Member
    MPM ASSET MANAGEMENT INVESTORS BV4 LLC     MPM BIO IV NVS STRATEGIC FUND, L.P.
    By: MPM BioVentures IV LLC, its Manager     By:   MPM BioVentures IV GP LLC,
            its General Partner
    By:  

        /s/ Luke Evnin

         
      Name: Luke Evnin     By:   MPM BioVentures IV LLC,
      Title:   Member       its Managing Member
          By:  

        /s/ Luke Evnin

            Name: Luke Evnin
            Title:   Member
    MPM BIOVENTURES IV GP LLC     MPM BIOVENTURES IV LLC
    By:   MPM BioVentures IV LLC,     By:  

        /s/ Luke Evnin

      its Managing Member     Name:   Luke Evnin
          Title:   Member
    By:  

        /s/ Luke Evnin

         
    Name:   Luke Evnin      
    Title:   Member      
    By:  

        /s/ Luke Evnin

        By:  

        /s/ Ansbert Gadicke

      Name: Luke Evnin       Name: Ansbert Gadicke
    By:  

        /s/ Todd Foley

         
      Name: Todd Foley      

    EXHIBITS

     

    A:

    Joint Filing Agreement

     

    Page 14 of 15

    Get the next $CHMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHMA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Chiasma, Inc.

      EFFECT - CHIASMA, INC (0001339469) (Filer)

      8/12/21 12:15:07 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Chiasma, Inc.

      15-12B - CHIASMA, INC (0001339469) (Filer)

      8/11/21 4:31:58 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Chiasma, Inc.

      S-8 POS - CHIASMA, INC (0001339469) (Filer)

      8/6/21 3:17:41 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q1 2022 Results

      Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

      5/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $CHMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)

      SC 13G/A - CHIASMA, INC (0001339469) (Subject)

      8/9/21 4:06:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/24/21 4:29:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/7/21 4:29:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CHMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CHMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chiasma downgraded by Jefferies

      Jefferies downgraded Chiasma from Buy to Hold

      5/6/21 8:05:49 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Chiasma with a new price target

      HC Wainwright resumed coverage of Chiasma with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      3/2/21 7:26:29 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/9/21 5:01:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: LUDLAM WILLIAM returned 11,799 units of Common Stock to the company, closing all direct ownership in the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:05:08 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Mamluk Roni

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:00:07 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CHMA
    Leadership Updates

    Live Leadership Updates

    See more
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

      Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar

      3/4/21 4:01:00 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care